- InselTRScolnickEMCure therapeutics and strategic prevention: raising the bar for mental health research.Mol Psychiatry.200611111716355250
- National Institutes of Mental Health. Facts about NIMH. Available at: http://www.nimh. nih.gov/about/nimh.cfm. Accessed August 8. 2006
- RothBLShefflerDJKroezeWKMagic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. WatRev Drug Discov.20043353359
- SpeddingMJayTCosta eSilva JPerretLA pathophysiological paradigm for the therapy of psychiatric disease.Nat Rev Drug Discov.2005446747615931256
- KaneJHonigfieldGSingerJMeltzerHYGroup atCCSClozapine for the treatment-resistant schizophrenic.Arch Gen Psychiatry.1988457897963046553
- McEvoyJPLiebermanJAStroupTSDavisSMMeltzerHYRosenheckRAet al.Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.Am J Psychiatry.200616360061016585434
- VenterJCAdamsMDMyersEWLiPWMuralRJSuttonGGet al.The sequence of the human genome.Science.20012911304135111181995
- HarrisonPJWeinbergerDRSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.Mol Psychiatry.200510406815263907
- InselTRCollinsFSPsychiatry in the genomics era.Am J Psychiatry.200316061662012668345
- SawaASnyderSHSchizophrenia: neural mechanisms for novel therapies.Mol Med.200393912765334
- HymanSENestlerEJInitiation and adaptation: a paradigm for understanding psychotropic drug action.Am J Psychiatry.19961531511628561194
- CarlssonMCarlssonASystems within the basal ganglia: implications for schizophrenia and Parkinson's disease.Trends Neurosci.1990132722761695402
- CarlssonAThe current status of the dopamine hypothesis of schizophrenia.Neuropsychopharmacology.198811791863075131
- MeltzerHYClinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.Psychopharmacology.198999S18S272682729
- JavittDCZukinSRRecent advances in the phencyclidine model of schizophrenia.Am J Psychiatry.1991148130113081654746
- FreedmanRAdlerLEBickfordPet al.Schizophrenia and nicotinic receptors.Harv Rev Psychiatry.199421791929384901
- FreedmanRCoonHMyles-WorsleyMet al.Linkage of a neurophysiological deficit in schizophrenia to a chromosome 1 5 locus.Proc Natl Acad SciUSA.199794587592
- FreedmanRHallMAdlerLELeonardSEvidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.Biol Psychiatry.19953822337548469
- MartinLFKemWRFreedmanRAlpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.Psychopharmacology (Bert).20041745464
- NeubigRRSpeddingMKenakinTChristopoulosAInternational Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology.Pharmacol Rev.20035559760614657418
- MorphyRKayCRankovicZFrom magic bullets to designed multiple ligands.Drug DiscovToday.20049641651
- RecanatiniMPoluzziEMasettiMCavalliADe PontiFQT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.Med Res Rev.20042513316615389727
- RothmanRBBaumannMHSavageJERauserLMcBrideAHufeisenSJet al.Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.Circulation.20001022836284111104741
- LessardEYessineMAHamelinBAO'HaraGLeBlancJTurgeonJInfluence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.Pharmacogenetics.1999943544310780263
- HopkinsALGroomCRThe druggable genome.Nat Rev Drug Discov.2002172773012209152
- RussAPLampelSThe druggable genome: an update.Drug Discov Today.2005101607161016376820
- StefanssonHSigurdssonESteinthorsdottirVet al.Neuregulin 1 and susceptibility to schizophrenia.Am J Hum Genet.20027187789212145742
- StraubREJiangYMacLeanCJet al.Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia.Ami J Hum Genet.200271337348
- St ClairDBlackwoodDMuirWet al.Association within a family of a balanced autosomal translocation with major mental illness.Lancet.199033613161973210
- HarrisonPJOwenMJGenes for schizophrenia? Recent findings and their pathophysiological implications.Lancet.200336141741912573388
- VorthermsTARothBLReceptorome screening for CNS drug discovery.Drugs.20058491496
- ArmbrusterBNRothBLMining the receptorome.J Biol Chem.20052805129513215590622
- FliriAFLogingWTThadeioPFVolkmannRABiological spectra analysis: Linking biological activity profiles to molecular structure.Proc Natl Acad SciUSA.2005102261266
- KroezeWKHufeisenSJPopadakBAet al.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology.20032851952612629531
- WirshingDAWirshingWCKysarLet al.Novel antipsychotics: comparison of weight gain liabilities.J Clin Psychiatry.1999603586310401912
- MorphyRRankovicZDesigned multiple ligands. An emerging drug discovery paradigm.J Med Chem.2005486523654316220969
- GeyerMAEllenbroekBAnimal behavior models of the mechanisms underlying antipsychotic atypicality.Prog Neuropsychopharmacol Biol Psychiatry.2003271071107914642967
- VartyGBBakshiVPGeyerMAM100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats.Neuropsychopharmacology.19992031132110088132
- PotkinSGShipleyJBeraRet al.Clinical and PET Effects of M100907, a selective 5HT-2A receptor antagonist.Schizophr Res.200149242
- MeltzerHYArvanitisLBauerDReinWPlacebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.Am J Psychiatry.200416197598415169685
- EllenbroekBAAnimal models in the genomic era: possibilities and limitations with special emphasis on schizophrenia.Behav Pharmacol.20031440941714501254
- CostaEChenYDavisJet al.REELIN and schizophrenia: a disease at the interface of the genome and the epigenome.Moi Interv.20022475714993361
- TremolizzoLCarboniGRuzickaWBet al.An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability.Proc Natl Acad Sci U S A.200299170951710012481028
- AbdolmalekyHMChengKHRussoAet al.Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report.Am J Med Genet B Neuropsychiatr Genet.2005134606615717292
- GraysonDRJiaXChenYet al.Reelin promoter hypermethylation in schizophrenia.Proc Natl Acad Sci U S A.20051029341934615961543
- BergerGEWoodSMcGorryPDIncipient neurovulnerability and neuroprotection in early psychosis.Psychopharmacol Bull.2003377910114566217
- de HaanLBakkerJMOverview of neuropathological theories of schizophrenia: from degeneration to progressive developmental disorder.Psychopathology.2004371714988644
- McGlashanTHZipurskyRBPerkinsDet al.Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.Am J Psychiatry.200616379079916648318
Dialogues in Clinical Neuroscience
Volume 8, 2006 - Issue 3